U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07290777) titled 'VEL-101 to Prevent Rejection After Kidney Transplantation' on Nov. 24.
Brief Summary: This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Transplantation, Kidney
Intervention:
DRUG: Tacrolimus (TAC)
Tacrolimus Immediate Release in addition to SOC
DRUG: VEL-101
VEL-101 in addition to SOC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Veloxis Pharmaceuticals
Published by HT Digital Content Services with permission from Health Daily Digest....